Highlights

International Good Elevator Automation Technique Industry 2020 Outlook Highlights Main Chances, Advance Engineering, Best Corporations Analysis to 2025

The MarketWatch News Department was not involved in the development of this written content.

Feb 03, 2021 (CDN Newswire through Comtex) —
Worldwide Smart Elevator Automation System Marketplace 2020 by Companies, Areas, Variety and Software, Forecast to 2025 interprets sector overview, worth chain framework, industrial environment, regional evaluation, purposes, sector size, and forecast. The report is a single of the most extensive and important additions to our archive of market place analysis scientific tests. The report provides an extensive investigation of market level of competition, regional growth, and industry segmentation by kind, application, and geography supported by correct industry figures. The report discusses different expansion drivers, market challenges and restraints, and tendencies, and chances in depth. It focuses on the worldwide Clever Elevator Automation Process market developments, upcoming forecasts, growth prospects, crucial conclusion-consumer industries, and current market gamers. The aims of the examine are to existing the key developments of

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

SAN DIEGO, Jan. 11, 2021 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlights progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises and announces a new development program for postoperative nausea and vomiting (PONV).

Recent Corporate Progress

Pain Management Franchise

  • New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of May 12, 2021.
  • Low Dose HTX-034 Produced Greater Pain Reduction to Bupivacaine, the Current Standard-of-Care, Through 96 hours in Bunionectomy Study: In the Phase 1b portion

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.

“I’m exceptionally proud of the entire Magenta team who continued to adapt and execute across our portfolio, despite the disruptions that characterized 2020. This past year, we continued to drive our vision to bring immune and blood systems reset to more patients. We announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023. We continue to advance four

AVEO Oncology Highlights Recent Progress and 2021 Outlook

BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook.

“We remain keenly focused on building out our commercial team ahead of the potential U.S. launch of tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC), including the addition of Dr. Corinne Epperly to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “If approved, we believe tivozanib has the potential to serve as a new treatment for the rapidly growing population of patients with relapsed or refractory RCC. In support of the further clinical and commercial development of tivozanib, we have identified opportunities to potentially extend its patent exclusivity period.”

Mr. Bailey added: “In addition to our launch preparation, we continue to make great progress advancing our clinical pipeline, with each asset expected to reach an important milestone this year. These

Global Poisonous Gasoline Masks Sector 2020 Outlook Highlights Important Possibilities, Advance Technological know-how, Major Corporations Investigation to 2025

The MarketWatch Information Department was not associated in the generation of this content.

Jan 17, 2021 (CDN Newswire through Comtex) —
The newest study on International Poisonous Gas Masks Sector 2020 by Brands, Sort and Software, Forecast to 2025 handles phase outlook, business assessment, opposition state of affairs, developments, and forecast by approaching yrs. The report supplies facts and the advancing small business collection details in the sector to the trade. The report emphasizes the key driving and restraining forces for this marketplace. It offers an analytical inspection of the world-wide Toxic Fuel Masks industry primarily based on a variety of segments. The marketplace has the summary and innovations size of the marketplace owing to the a variety of outlook opportunities. The report delivers a complete of the upcoming developments and developments of the current market. A detailed study accumulated to give the most recent insights about features of the

The Zacks Analyst Website Highlights: Taiwan Semiconductor Manufacturing, Micron Technologies, Electric power Integrations, Cree and Maxim Built-in Solutions

For Fast Release

Chicago, IL – January 18, 2021 – Zacks.com announces the checklist of shares featured in the Analyst Web site. Each and every working day the Zacks Fairness Investigation analysts discuss the most up-to-date news and activities impacting stocks and the economical markets. Stocks not long ago featured in the weblog consist of: Taiwan Semiconductor Manufacturing Company Constrained TSM, Micron Technologies, Inc. MU, Electricity Integrations, Inc. POWI, Cree, Inc. CREE and Maxim Built-in Merchandise, Inc. MXIM.

Below are highlights from Friday’s Analyst Blog site:

TSM and CapEx Issue to Power in Semis

Earnings season has kicked off for the know-how sector and as usually, Taiwan Semiconductor’s numbers offer you perception into other players.

The firm reported strong profits and earnings, which grew a respective 22.% and 32.9% over final calendar year.

Management attributed the energy to its major edge 5 nm process (now 20% of complete wafer revenue)

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials – Press Release

CAMBRIDGE, Mass.–(Business Wire)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.

“I’m exceptionally proud of the entire Magenta team who continued to adapt and execute across our portfolio, despite the disruptions that characterized 2020. This past year, we continued to drive our vision to bring immune and blood systems reset to more patients. We announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023. We continue

Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress

  • Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to start H1 2021 following successful U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) meetings earlier in the year.
  • Phase III study in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is currently opening for enrollment in Europe and is expected to open in the U.S. in Q1 2021.
  • Recent publication in American Journal of Pathology highlighting potential of nomacopan’s inhibition of C5 and LTB4 in treatment of uveitis and other back of the eye diseases such as age-related macular degeneration (AMD).
  • Lung program being expanded to include additional inflammatory lung conditions with major exacerbations, in addition to COVID-19 pneumonia.
  • New data from 19 PNH patients treated for over 30 cumulative patient-years show that self-administered nomacopan is well-tolerated and substantially reduces transfusion